ADC Review / Journal of Antibody-drug Conjugates

By InPress Media Group | ADC Review / Journal of Antibody-drug Conjugates (ISSN: 2327-0152) is an international peer reviewed publication. Key information includes peer-reviewed articles, news features, discussions, blogs, and a knowledge center offering the latest and most relevant information about Antibody Drug Conjugates (ADCs), BiSpecific Antibodies, Site Specific Antibody Drug Conjugates, Small Molecule Drug Conjugates (SMDC), and Engineered Antibody Fragments.

London Calling: The Cutting-edge of Novel ADC Technologies

Published on 24th March<p>Major players in the rapidly advancing field of antibody drug conjugates (ADCs) will meet in London, United Kingdom, on 23-24 …

Antibody Drug Conjugates News

05 April, 2017<p>Multiple data presentations supporting Seattle Genetics' advancing antibody-drug conjugate or ADC and immuno-oncology programs were …

Cancer

Early Detection: The New Cancer Paradigm

Published on 01st March<p><i>A seemingly healthy patient walks into the doctor’s office for a routine checkup. The doctor says: “I have good news and bad</i> …

Contract Manufacturing of Antibody-drug Conjugates – A Growing Market

Published on 21st February<p>The demand for manufacturing capacity of antibody-drug conjugates (ADCs), which includes a highly potent cytotoxic drug …

Developing the Next Generation of Clinically Successful Antibody-drug Conjugates

<b>About Peter Hofland</b><br>Peter Hofland, Ph.D is the Executive Editor of ADC Review/Journal of Antibody-drug Conjugates, a comprehensive digital platform …

Brentuximab Vedotin Identified as Potentially Transformational in Hodgkin’s lymphoma Treament

Published on 16th December<p>Earlier this month, during the <i>57th Annual Meeting and Exposition of the American Society of Hematology (ASH)</i>, held in …

First Patient Dosed in Phase I Trial of ADCT-402 in CD-19 Positive B-cell Non-Hodgkin Lymphomas

Published on 14th March<p>Late last week, Swiss based ADC Therapeutics, an oncology drug development company that specializes in the development of …

Commercial and Regulatory Progress under Brentuximab Vedotin Collaboration Between Seattle Genetics and Takeda

Published on 04th February<p>Nearly 7 years ago, in 2009, Seattle Genetics, a clinical stage biopharmaceutical company, and Takeda Pharmaceuticals, …

Novel ADC Technology Demonstrated Strong Preclinical Antitumor Activity in B-cell Malignancies – Moves to Phase I

Published on 01st March<p>Lymphomas, a group of cancers that originate in the lymphatic system, include both <i>Hodgkin lymphoma</i> (HL) and <i>non-Hodgkin …

Synaffix’s New High Potency Lab now Fully Operational to Support Growing Collaboration With Biotech and Pharma

Published on 24th February<p>Late last week, Synaffix, a Dutch biotechnology company backed by a top tier, life science-focused, investor syndicate and …

Vadastuximab Talirine (SGN-CD33A) Combination Therapy Evaluates Safety and Activity for Patients with Untreated Myelodysplastic Syndrome

Published on 22nd February<p>A new phase I/II clinical trial of vadastuximab talirine, also known as SGN-CD33A; 33A (Seattle Genetics), in combination …

Strategic Collaboration Between CMC Biologics and IDT Biologika to Manufacture Antibody Drug Conjugates

Published on 18th February<p>Denmark-based CMC Biologics, a company involved in the clinical and commercial manufacturing of monoclonal antibodies and …

First Patient Dosed in Phase I Trial of ADCT-301 Trial

Published on 10th February<p>Earlier this month ADC Therapeutics, a Swiss-based oncology drug development company, dosed the first patient in a Phase I …

Sacituzumab Govitecan Receives Breakthrough Therapy Designation for Triple-negative Breast Cancer

Published on 08th February<p>The investigational antibody-drug conjugate, sacituzumab govitecan, also know as IMMU-132 (Immunomedics), has received …

Study Links Gemtuzumab Ozogamicin Response in Pediatric AML to Expression Level of CD33

Published on 04th February<p>Expression CD33 is largely restricted to hematopoietic cells. [1] Because CD33 is consistently expressed on <i>acute myeloid</i> …

Breakthrough Therapy Designation for Sacituzumab Govitecan in Triple-negative Breast Cancer

Published on 06th February<p>Sacituzumab govitecan, also known as IMMU-132, has received Breakthrough Therapy Designation from the U.S. Food and Drug …

Piramal Expands Coldstream Laboratories’ ADC Capacity

Published on 04th February<p>Piramal Pharma Solutions has confirmed that it is planning an expansion Coldstream Laboratories, its sterile injectable …

Mersana and Takeda Expand Partnership to Advance Development of Fleximer® based Antibody-Drug Conjugates

Published on 03rd February<p>Mersana Therapeutics and Takeda Pharmaceutical Company Limited announced that they have entered a new, expanded, strategic …

Survival Benefit of Ado-trastuzumab Emtansine in Heavily Pretreated HER2+ Breast Cancer Patients Confirmed in Various Studies

Published on 02nd February<p>Study results from the phase III TH3RESA clinical trial presented during the 38th San Antonio Breast Cancer Symposium …

Advancements in Bispecific Antibody Immunotherapy Development

Published on 02nd February<p>The 15th annual <i>Cambridge Healthcare Institute’s PepTalk – Protein Science Week</i>, one of the largest gatherings of protein …

European Commission Approves Label Variation for Brentuximab Vedotin

Published on 24th January<p>The European Commission (EC) has, earlier this week, approved a Type II variation for brentuximab vedotin (Adcetris®; …

Cancer

Blinatumomab Shows Positive Outcomes in Acute Lymphoblastic Leukemia

Published on 22nd January<p>Data presented during the 57th Annual Meeting and Exposition of the <i>American Society of Hematology</i> (ASH) in Orlando, Florida …

Pfizer Exercises Options As Part of License Agreement with Philogen

Published on 21st January<p>Swiss-Italian Philogen, a clinical-stage biotechnology company engaged in the discovery and development of novel …

CytomX Therapeutics and Bristol-Myers Squibb Continue Collaboration

Published on 20th January<p>CytomX Therapeutics, an oncology-focused biopharmaceutical company based in South San Francisco developing investigational …

Lonza Expands it’s Mammalian Production Capacity

Published on 13th January<p>Over the last decade, biologics, including monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), therapeutic …

Roche and Catalent Start Research Collaboration on SMARTAG™ Technology

Published on 13th January<p>New Jersey based Catalent has agreed to a research collaboration with Roche to develop next-generation molecules coupling …

Biology

Targeting Breast Cancer with more Punch

Published on 11th January<p>To optimize current treatment and develop methods to more efficiently treat breast cancer, scientists have been researching …

Immunomedics Receives U.S. patent for Labetuzumab Govitecan

Published on 05th January<p>Earlier this week Immunomedics announced the issuance of U.S. patent no. 9,226,973 for additional claims. Under the patent …

Cancer

Sacituzumab Govitecan Continues to show Positive Results in the Treatment of Heavily Pre-treated Metastatic Triple-Negative Breast Cancer Patients

Published on 22nd December<p>Updated results from a Phase II clinical study of sacituzumab govitecan, also known as IMMU-132, in patients with …